{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:40:01Z","timestamp":1792172401017,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"Horizon 2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["861323"],"award-info":[{"award-number":["861323"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cmi.2023.03.018","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T03:50:21Z","timestamp":1679543421000},"page":"845-857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"29","author":[{"given":"Maria","family":"Sanz-Codina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haktan \u00d6vul","family":"Bozkir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anselm","family":"Jorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.03.018_bib1","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1097\/CCM.0000000000004899","article-title":"Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU","volume":"49","author":"Alhazzani","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2023.03.018_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-018-2178-7","article-title":"A\u00a0complete and multifaceted overview of antibiotic use and infection diagnosis in the intensive care unit: results from a prospective four-year registration","volume":"22","author":"De Bus","year":"2018","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2023.03.018_bib3","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","article-title":"Time to treatment and mortality during mandated emergency care for sepsis","volume":"376","author":"Seymour","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.03.018_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrmicro2333","article-title":"How antibiotics kill bacteria: from targets to networks","volume":"8","author":"Kohanski","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2023.03.018_bib5","doi-asserted-by":"crossref","first-page":"E3463","DOI":"10.1073\/pnas.1717295115","article-title":"Global increase and geographic convergence in antibiotic consumption between 2000 and 2015","volume":"115","author":"Klein","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2023.03.018_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-05505-6","article-title":"The use of antibiotics in the intensive care unit of a tertiary hospital in Malawi","volume":"20","author":"Kayambankadzanja","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.018_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002158","article-title":"Selection of resistant bacteria at very low antibiotic concentrations","volume":"7","author":"Gullberg","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cmi.2023.03.018_bib8","doi-asserted-by":"crossref","first-page":"xtaa004","DOI":"10.1093\/femsmc\/xtaa004","article-title":"Issues beyond resistance: inadequate antibiotic therapy and bacterial hypervirulence","volume":"1","author":"Goneau","year":"2020","journal-title":"FEMS Microbe"},{"key":"10.1016\/j.cmi.2023.03.018_bib9","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","article-title":"What antibiotic exposures are required to suppress the emergence of resistance for Gram-negative bacteria? A systematic review","volume":"58","author":"Sumi","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2023.03.018_bib10","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3390\/pharmaceutics14081585","article-title":"Relationship between pharmacokinetic\/pharmacodynamic target attainment and microbiological outcome in critically ill COVID-19 patients with documented Gram-negative superinfections treated with TDM-guided continuous-infusion meropenem","volume":"14","author":"Sanz Codina","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cmi.2023.03.018_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000635","article-title":"Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial","volume":"2","author":"Jensen","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2023.03.018_bib12","first-page":"87","article-title":"Pharmacokinetic variability of beta-lactams in critically ill patients: a narrative review","volume":"39","author":"Boidin","year":"2020","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.cmi.2023.03.018_bib13","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u00df-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.018_bib14","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1186\/cc13874","article-title":"Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study","volume":"18","author":"Blot","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2023.03.018_bib15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jcrc.2007.11.011","article-title":"Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study","volume":"23","author":"van Zanten","year":"2008","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.cmi.2023.03.018_bib16","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.018_bib17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2023.03.018_bib18","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2023.03.018_bib19","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2023.03.018_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/FTD.0000000000000942","article-title":"Therapeutic drug monitoring of antibiotics in critically ill patients: current practice and future perspectives with a focus on clinical outcome","volume":"44","author":"Koch","year":"2022","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cmi.2023.03.018_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2023.03.018_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13054-022-04098-7","article-title":"Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial","volume":"26","author":"Roggeveen","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2023.03.018_bib23","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s00134-022-06921-9","article-title":"Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial","volume":"48","author":"Ewoldt","year":"2022","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2023.03.018_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.cmi.2023.03.018_bib28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(96)90060-0","article-title":"Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies","volume":"60","author":"Fern\u00e1ndez de Gatta","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2023.03.018_bib29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0924-8579(02)00188-7","article-title":"TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients","volume":"20","author":"Pea","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2023.03.018_bib34","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.018_bib30","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2023.03.018_bib31","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/jac\/dkv123","article-title":"Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial","volume":"70","author":"Sime","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.03.018_bib35","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/tid.12454","article-title":"Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial","volume":"17","author":"Neofytos","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.018_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01818-17","article-title":"Impact of real-time therapeutic drug monitoring on the prescription of antibiotics in burn patients requiring admission to the intensive care unit","volume":"62","author":"Fournier","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.03.018_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cmi.2023.03.018_bib26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2023.03.018_bib27","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2023.03.018_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.018_bib37","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1128\/AAC.00951-13","article-title":"Protein binding of \u03b2-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.03.018_bib38","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/FTD.0000000000000809","article-title":"Comment on \u201cmeropenem, cefepime, and piperacillin protein binding in patient samples","volume":"42","author":"Al-Shaer","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cmi.2023.03.018_bib39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dkac400","article-title":"Comparison of ultrafiltration and microdialysis for ceftriaxone protein-binding determination","volume":"78","author":"Sanz-Codina","year":"2023","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.03.018_bib40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40262-021-01102-1","article-title":"Biomarkers predicting tissue pharmacokinetics of antimicrobials in sepsis: a review","volume":"61","author":"Sanz Codina","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2023.03.018_bib41","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3390\/antibiotics10121485","article-title":"Predicting antimicrobial activity at the target site: pharmacokinetic\/pharmacodynamic indices versus time-kill approaches","volume":"10","author":"van Os","year":"2021","journal-title":"Antibiot (Basel)"},{"key":"10.1016\/j.cmi.2023.03.018_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01649-19","article-title":"Building a better test for piperacillin-tazobactam susceptibility testing: would that it were so simple (it\u2019s complicated)","volume":"58","author":"Henderson","year":"2020","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2023.03.018_bib43","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development\u2014part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cmi.2023.03.018_bib44","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00228-020-02922-z","article-title":"External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients","volume":"76","author":"Wang","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2023.03.018_bib45","first-page":"64","article-title":"Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms","volume":"20","author":"Rybak","year":"1986","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.cmi.2023.03.018_bib46","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/cid\/ciac506","article-title":"Beta-lactam antibiotic therapeutic drug monitoring in critically ill patients: a systematic review and meta-analysis","volume":"75","author":"Mangalore","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.018_bib47","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2019"},{"key":"10.1016\/j.cmi.2023.03.018_bib48","first-page":"611","article-title":"Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional study","volume":"22","author":"Ewoldt","year":"2022","journal-title":"BMC\u00a0Infect\u00a0Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23001349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23001349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:35:00Z","timestamp":1761118500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X23001349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1198743X23001349"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.03.018","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}